Rhumbline Advisers Buys 30,286 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Rhumbline Advisers grew its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 14.9% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 233,217 shares of the company’s stock after acquiring an additional 30,286 shares during the period. Rhumbline Advisers owned about 0.08% of Amneal Pharmaceuticals worth $1,481,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Rothschild Investment LLC bought a new position in Amneal Pharmaceuticals during the second quarter valued at $26,000. Atlanta Consulting Group Advisors LLC bought a new position in shares of Amneal Pharmaceuticals during the 1st quarter worth $61,000. nVerses Capital LLC purchased a new stake in Amneal Pharmaceuticals in the 2nd quarter worth about $62,000. Trexquant Investment LP purchased a new stake in Amneal Pharmaceuticals in the 4th quarter worth about $65,000. Finally, Bayesian Capital Management LP bought a new stake in Amneal Pharmaceuticals in the 1st quarter valued at about $65,000. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on AMRX shares. Truist Financial lifted their target price on shares of Amneal Pharmaceuticals from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price objective for the company in a research note on Friday, September 6th. Finally, Barclays increased their target price on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 13th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

Amneal Pharmaceuticals Price Performance

AMRX stock opened at $8.70 on Friday. The firm has a 50 day moving average of $7.95 and a 200-day moving average of $6.87. The firm has a market capitalization of $2.69 billion, a P/E ratio of -15.54 and a beta of 1.18. Amneal Pharmaceuticals, Inc. has a 12 month low of $3.36 and a 12 month high of $8.90. The company has a current ratio of 1.33, a quick ratio of 0.82 and a debt-to-equity ratio of 121.31.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its earnings results on Friday, August 9th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.04. The business had revenue of $701.78 million for the quarter, compared to analysts’ expectations of $657.43 million. Amneal Pharmaceuticals had a negative net margin of 6.72% and a positive return on equity of 1,235.03%. As a group, sell-side analysts predict that Amneal Pharmaceuticals, Inc. will post 0.52 earnings per share for the current fiscal year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.